Y Intercept Hong Kong Ltd Purchases 26,564 Shares of Indivior PLC $INDV

Y Intercept Hong Kong Ltd grew its position in Indivior PLC (NASDAQ:INDV) by 104.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,007 shares of the company’s stock after acquiring an additional 26,564 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Indivior were worth $1,254,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Goldman Sachs Group Inc. raised its stake in shares of Indivior by 18.4% in the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after purchasing an additional 1,299,425 shares in the last quarter. Jane Street Group LLC increased its holdings in Indivior by 2,597.9% in the 1st quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after buying an additional 958,132 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Indivior by 16.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock valued at $71,000 after buying an additional 666 shares in the last quarter. State of New Jersey Common Pension Fund D bought a new position in shares of Indivior during the 2nd quarter worth about $262,000. Finally, Amalgamated Bank acquired a new stake in shares of Indivior during the 2nd quarter valued at about $61,000. 60.33% of the stock is currently owned by institutional investors.

Indivior Stock Performance

Shares of INDV opened at $35.38 on Friday. The company has a market cap of $4.42 billion, a price-to-earnings ratio of 38.46 and a beta of 0.75. The stock has a fifty day moving average price of $34.84 and a two-hundred day moving average price of $27.92. Indivior PLC has a 52-week low of $7.62 and a 52-week high of $38.00.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.34. The company had revenue of $314.00 million during the quarter, compared to analyst estimates of $257.66 million. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%. As a group, research analysts predict that Indivior PLC will post 1.22 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director David E. Wheadon acquired 1,771 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was purchased at an average price of $35.39 per share, for a total transaction of $62,675.69. Following the transaction, the director directly owned 14,395 shares of the company’s stock, valued at approximately $509,439.05. This trade represents a 14.03% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Barbara Ryan acquired 775 shares of Indivior stock in a transaction on Monday, January 5th. The shares were purchased at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the acquisition, the director owned 1,963 shares in the company, valued at approximately $69,470.57. This represents a 65.24% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders purchased 4,871 shares of company stock valued at $172,385.

Analysts Set New Price Targets

Several research firms recently issued reports on INDV. Craig Hallum reissued a “buy” rating and issued a $41.00 price target on shares of Indivior in a research report on Friday, October 31st. Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. Weiss Ratings restated a “hold (c)” rating on shares of Indivior in a research report on Wednesday. Morgan Stanley reiterated an “overweight” rating and issued a $36.00 price target on shares of Indivior in a research report on Wednesday, December 3rd. Finally, Northland Securities set a $50.00 price objective on Indivior in a report on Tuesday, January 20th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $39.33.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.